Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 09 2023
09 09 2023
Historique:
received:
23
04
2023
accepted:
06
09
2023
medline:
11
9
2023
pubmed:
10
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
This study aimed to evaluate the efficacy of favipiravir (FPV) in preventing the development of severe COVID-19 in patients with mild-to-moderate symptoms. The study evaluated 1037 COVID-19 patients treated with FPV or standard treatment between April and September 2021, analyzed by propensity score matching. 149 patients were included in each arm after propensity score matching. The clinical outcomes showed no deterioration of the WHO clinical progression scale in the FPV group compared to the standard treatment group on day 5 (83.2% vs. 69.1%, p < 0.001). The WHO clinical progression scale also showed improvements on day 14 in the FPV group compared to the standard treatment group (66.4% vs. 46.3%, p < 0.001). The rates of oxygen supplementation and hospitalization were significantly lower in the FPV group compared to the standard treatment group (0% vs. 12.1% and 0.7% vs. 17.4%, respectively, p < 0.001 for both). There were no differences in adverse events between the two groups. The study highlights the effectiveness of FPV in preventing severe COVID-19 and hospitalization in patients with mild-to-moderate symptoms. The findings emphasize the importance of personalized treatment plans for COVID-19 patients, starting FPV treatment early, and adjusting dosages based on ethnicity and body weight.
Identifiants
pubmed: 37689754
doi: 10.1038/s41598-023-42195-x
pii: 10.1038/s41598-023-42195-x
pmc: PMC10492810
doi:
Substances chimiques
favipiravir
EW5GL2X7E0
Amides
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14884Informations de copyright
© 2023. Springer Nature Limited.
Références
Emerg Microbes Infect. 2022 Dec;11(1):2197-2206
pubmed: 35997325
BMC Infect Dis. 2021 May 27;21(1):489
pubmed: 34044777
EClinicalMedicine. 2022 Oct 20;54:101703
pubmed: 36284645
Clin Pharmacokinet. 2016 Aug;55(8):907-23
pubmed: 26798032
Clin Infect Dis. 2022 Aug 24;75(1):e432-e439
pubmed: 34849615
J Antimicrob Chemother. 2021 Jul 15;76(8):2121-2128
pubmed: 34075418
Br J Clin Pharmacol. 2021 Mar;87(3):707-711
pubmed: 32515023
Antibiotics (Basel). 2022 Jun 15;11(6):
pubmed: 35740211
Int J Infect Dis. 2021 Feb;103:62-71
pubmed: 33212256
J Infect Dis. 2021 Aug 2;224(3):415-419
pubmed: 33961695
Sci Rep. 2021 May 26;11(1):11022
pubmed: 34040117
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Antiviral Res. 2020 Sep;181:104866
pubmed: 32659293
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Clin Respir J. 2021 Mar;15(3):293-309
pubmed: 33090710
Medicina (Kaunas). 2023 Jun 06;59(6):
pubmed: 37374302
Virol J. 2020 Sep 24;17(1):141
pubmed: 32972430
Antimicrob Agents Chemother. 2020 Nov 17;64(12):
pubmed: 32958718
Clin Infect Dis. 2023 Feb 8;76(3):e10-e17
pubmed: 36065065
Br J Clin Pharmacol. 2022 Jul;88(7):3516-3522
pubmed: 35014080
Clin Microbiol Infect. 2022 Apr;28(4):602-608
pubmed: 35026375
CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1161-1170
pubmed: 34292670
J Infect Chemother. 2021 Jul;27(7):1051-1057
pubmed: 33902990
Int J Infect Dis. 2021 Jan;102:501-508
pubmed: 33130203